SYNCOMF · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 59/100 — Quality 72 · Valuation 75 · Momentum 0
| Share price | ₹13.57 |
| Market cap | ₹1,333 Cr |
| P/E ratio | 17.5 |
| P/B ratio | 3.5 |
| ROE | 81.3% |
| ROCE | 23.8% |
| Book value | ₹4.10 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹489 Cr | ₹76 Cr | 16.0% |
| 2025 | ₹463 Cr | ₹49 Cr | 12.0% |
| 2024 | ₹262 Cr | ₹25 Cr | 11.0% |
| 2023 | ₹222 Cr | ₹20 Cr | 9.0% |
| 2022 | ₹216 Cr | ₹20 Cr | 9.0% |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus br